It is not all doom and gloom for Asia based on the healthcare companies’ market performance amidst the global Covid-19 pandemic backdrop dominating headlines across the globe. The S&P Pan Asia ex-JANZ Health Care 50 Index increased by 33.6% over the last 3 months. The other 2 South East Asian (“SEA”) countries with healthcare market indices measuring the market performance of its listed healthcare companies are iEdge SG All Healthcare Index in Singapore and Bursa Malaysia Health Care Index in Malaysia.
The upwards trend observed for S&P Pan Asia ex-JANZ Health Care 50 Index was similarly observed for iEdge SG All Healthcare Index and Bursa Malaysia Health Care Index, but with a much higher percentage increase. In the last 3 months, the iEdge SG All Healthcare Index and Bursa Malaysia Health Care Index increased by 68.4% and 165.9% respectively.
In this article, we aim to set out:
- Healthcare sector market update in Singapore identifying the drivers behind the change in
market equity value for key healthcare companies and their key trading multiples; - Healthcare market indices trend in Asia for the last 3 years; and
- Healthcare M&A activities trend for the last 3 years and completed deals in South East Asia
in 2020.
DISCLAIMER: All opinions, conclusions, or recommendations in this article are reasonably held by Baker Tilly at the time of compilation but are subject to change without notice to you. Whilst every effort has been made to ensure the accuracy of the contents in this article, the information in this article is not designed to address any particular circumstance, individual or entity. Users should not act upon it without seeking professional advice relevant to the particular situation. We will not accept liability for any loss or damage suffered by any person directly or indirectly through reliance upon the information contained in this article.
Related content
